What’s On CEO Andrew Witty’s To-Do List Before Exiting GSK

The company showed signs of stabilization in the first quarter, as Witty insisted his diversified strategy is beginning to pay off. But a new CEO will have to contend with the potential entry of Advair generics.

Andrew Witty (GSK)
Andrew Witty • Source: GSK

GlaxoSmithKline PLC CEO Andrew Witty has a year left on the job, time he would like to use to convince investors his diversified strategy is the right one for the company. The UK drug maker delivered 8% sales growth and an 8% increase in core earnings growth in the first quarter, driven by vaccines and consumer health care – signs that the strategy is gaining momentum.

Pharmaceuticals sales fell 1% to £3.59bn ($5.22bn), but management said the business is on track to return to growth in...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from Business

More from Scrip